ALEC-04 is under clinical development by Alentis Therapeutics and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ALEC-04’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ALEC-04 overview

ALEC-04 is under development for the treatment of solid tumor, hepatocellular carcinoma, cholangiocarcinoma and recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC). It acts by targeting claudin 1 (CLDN1).

Alentis Therapeutics overview

Alentis Therapeutics (Alentis) is biotech company that develops treatments for fibrotic disease and associated cancer. The company addresses the unmet medical needs of patients through the development of medication based on the discovery of the CLDN-1 Protien. the companie’s pipeline portfolio includes: ALE.C04, It has been developed to directly target the cancer while scilencing the CLDN1-mediated carcinogenic signaling and opening up the stiff extracellular matrix (ECM) in tumors with immune evasive properties. ALE.F02, has been developed with a silenced effector function to target the stiff ECM of fibrotic tissues and organs, which also under development for kidney, lung, and liver fibrosis. Alentis is headquartered in Basel, Switzerland.

For a complete picture of ALEC-04’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.